$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw

$avrw Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000147793224004816 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$192.0K	$287.0K	$972.0K
YoY Change	-81.08%	-70.47%	-13.45%
Cost Of Revenue	$35.00K	$58.00K	$278.0K
YoY Change	-87.41%	-79.14%	85.33%
Gross Profit	$157.0K	$229.0K	$694.0K
YoY Change	-78.7%	-67.0%	-28.67%
Gross Profit Margin	81.77%	79.79%	71.4%
Selling, General & Admin	$660.0K	$944.0K	$2.542M
YoY Change	-71.19%	-62.86%	-18.53%
% of Gross Profit	420.38%	412.23%	366.28%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%	100.0%
% of Gross Profit	0.64%	0.44%	0.14%
Operating Expenses	$660.0K	$944.0K	$2.190M
YoY Change	-71.42%	-56.89%	-71.75%
Operating Profit	-$503.0K	-$715.0K	-$1.496M
YoY Change	-68.0%	-52.21%	-77.94%
Interest Expense		-$5.000K	$13.00K
YoY Change		-138.46%	-93.19%
% of Operating Profit
Other Income/Expense, Net	-$38.00K	-$179.0K	$509.0K
YoY Change	-94.17%	-135.17%	-437.09%
Pretax Income	-$541.0K	-$894.0K	-$987.0K
YoY Change	-75.67%	-9.42%	-85.76%
Income Tax	$0.00	$3.000K	$0.00
% Of Pretax Income
Net Earnings	-$541.0K	-$897.0K	-$987.0K
YoY Change	-75.67%	-9.12%	-89.74%
Net Earnings / Revenue	-281.77%	-312.54%	-101.54%
Basic Earnings Per Share
Diluted Earnings Per Share		-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	77.99M shares	77.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$19.00K	$175.0K
YoY Change		-89.14%	243.14%
Cash & Equivalents	$11.00K	$19.00K	$175.0K
Short-Term Investments
Other Short-Term Assets	$15.00K	$7.000K	$47.00K
YoY Change	-72.73%	-85.11%	-60.83%
Inventory	$142.0K	$151.0K	$281.0K
Prepaid Expenses	$8.000K	$15.00K	$11.00K
Receivables	$33.00K	$49.00K	$170.0K
Other Receivables		$0.00	$2.050M
Total Short-Term Assets	$238.0K	$320.0K	$2.823M
YoY Change	-87.96%	-88.66%	-86.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.000K	$3.000K	$3.000K
YoY Change	50.0%	0.0%	0.0%
Goodwill
YoY Change
Intangibles	$212.0K	$218.0K
YoY Change
Long-Term Investments		$264.0K	$411.0K
YoY Change		-35.77%	90.28%
Other Assets		$36.00K	$36.00K
YoY Change		0.0%	-98.24%
Total Long-Term Assets	$510.0K	$710.0K	$888.0K
YoY Change	-39.64%	-20.05%	-90.28%
TOTAL ASSETS
Total Short-Term Assets	$238.0K	$320.0K	$2.823M
Total Long-Term Assets	$510.0K	$710.0K	$888.0K
Total Assets	$748.0K	$1.030M	$3.711M
YoY Change	-73.48%	-72.24%	-87.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.452M	$2.283M	$1.269M
YoY Change	56.08%	79.91%	-59.75%
Accrued Expenses	$1.587M	$1.453M	$1.474M
YoY Change	-6.15%	-1.42%	-48.3%
Deferred Revenue
YoY Change
Short-Term Debt		$67.00K	$585.0K
YoY Change		-88.55%	-84.3%
Long-Term Debt Due		$8.694M	$7.201M
YoY Change		20.73%	-39.06%
Total Short-Term Liabilities	$13.30M	$12.97M	$11.58M
YoY Change	3.96%	12.01%	-56.01%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$74.00K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities		$74.00K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.30M	$12.97M	$11.58M
Total Long-Term Liabilities		$74.00K	$0.00
Total Liabilities	$13.30M	$13.04M	$11.58M
YoY Change	3.96%	12.65%	-56.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$126.1M	-$125.6M	-$121.2M
YoY Change	2.23%	3.66%	10.93%
Common Stock	$78.00K	$78.00K	$72.00K
YoY Change	6.85%	8.33%	1.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.55M	-$12.01M	-$7.868M
YoY Change
Total Liabilities & Shareholders Equity	$748.0K	$1.030M	$3.711M
YoY Change	-73.48%	-72.24%	-87.34%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$541.0K	-$897.0K	-$987.0K
YoY Change	-75.67%	-9.12%	-89.74%
Depreciation, Depletion And Amortization	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%	100.0%
Cash From Operating Activities		-$314.0K	-$1.193M
YoY Change		-73.68%	-31.28%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$9.000K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		$360.0K
YoY Change
Cash From Investing Activities		$360.0K	-$9.000K
YoY Change		-4100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-56.00K	-63.00K
YoY Change		-11.11%	-105.02%
NET CHANGE
Cash From Operating Activities		-314.0K	-1.193M
Cash From Investing Activities		360.0K	-9.000K
Cash From Financing Activities		-56.00K	-63.00K
Net Change In Cash		-10.00K	-1.265M
YoY Change		-99.21%	163.54%
FREE CASH FLOW
Cash From Operating Activities		-$314.0K	-$1.193M
Capital Expenditures		$0.00	$9.000K
Free Cash Flow		-$314.0K	-$1.202M
YoY Change		-73.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7868000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	15000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	5000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1196000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001643301
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77993348	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77993348	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55908
	dei	Entity Registrant Name EntityRegistrantName	AVENIR WELLNESS SOLUTIONS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-1504639
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5805 Sepulveda Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 801
	dei	Entity Address City Or Town EntityAddressCityOrTown	Sherman Oaks
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91411
	dei	City Area Code CityAreaCode	424
	dei	Local Phone Number LocalPhoneNumber	273-8675
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	77993348	shares
CY2024Q2	avrw	Rvenue From Product Sales Net Of Discounts And Refunds RvenueFromProductSalesNetOfDiscountsAndRefunds	287000	usd
CY2023Q2	avrw	Rvenue From Product Sales Net Of Discounts And Refunds RvenueFromProductSalesNetOfDiscountsAndRefunds	949000	usd
	avrw	Rvenue From Product Sales Net Of Discounts And Refunds RvenueFromProductSalesNetOfDiscountsAndRefunds	727000	usd
	avrw	Rvenue From Product Sales Net Of Discounts And Refunds RvenueFromProductSalesNetOfDiscountsAndRefunds	2139000	usd
CY2024Q2	avrw	Revenue From Product Sales Through Related Party RevenueFromProductSalesThroughRelatedParty	0	usd
CY2023Q2	avrw	Revenue From Product Sales Through Related Party RevenueFromProductSalesThroughRelatedParty	23000	usd
	avrw	Revenue From Product Sales Through Related Party RevenueFromProductSalesThroughRelatedParty	0	usd
	avrw	Revenue From Product Sales Through Related Party RevenueFromProductSalesThroughRelatedParty	71000	usd
CY2024Q2	us-gaap	Revenues Revenues	287000	usd
CY2023Q2	us-gaap	Revenues Revenues	972000	usd
	us-gaap	Revenues Revenues	727000	usd
	us-gaap	Revenues Revenues	2210000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	58000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	278000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	152000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	539000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	229000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	694000	usd
	us-gaap	Gross Profit GrossProfit	575000	usd
	us-gaap	Gross Profit GrossProfit	1671000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	944000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2542000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2161000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5159000	usd
CY2024Q2	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	0	usd
CY2023Q2	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-352000	usd
	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	0	usd
	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-308000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	944000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2190000	usd
	us-gaap	Operating Expenses OperatingExpenses	2161000	usd
	us-gaap	Operating Expenses OperatingExpenses	4851000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-715000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1496000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1586000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3180000	usd
CY2024Q2	us-gaap	Interest Income Operating InterestIncomeOperating	1000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	32000	usd
CY2024Q2	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-174000	usd
CY2023Q2	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	507000	usd
	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-595000	usd
	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	1979000	usd
CY2024Q2	us-gaap	Interest Expense Other InterestExpenseOther	6000	usd
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	13000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	13000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	27000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-179000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	509000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-603000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1984000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-894000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-987000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2189000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-897000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-987000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2192000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1196000	usd
CY2024Q2	avrw	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.01
CY2023Q2	avrw	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.01
	avrw	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.03
	avrw	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.02
CY2024Q2	avrw	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	77993348	shares
CY2023Q2	avrw	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	71479697	shares
	avrw	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	77993348	shares
	avrw	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	71455716	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9886000	usd
CY2024Q1	avrw	Fair Value Of Stock Options Granted FairValueOfStockOptionsGranted	5000	usd
CY2024Q1	avrw	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	30000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1295000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-11146000	usd
CY2024Q2	avrw	Fair Value Of Stock Options Granted FairValueOfStockOptionsGranted	5000	usd
CY2024Q2	avrw	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	24000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-897000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-12014000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7105000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000	usd
CY2023Q1	avrw	Fair Value Of Stock Options Granted FairValueOfStockOptionsGranted	96000	usd
CY2023Q1	avrw	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	113000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-209000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-7103000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	32000	usd
CY2023Q2	avrw	Fair Value Of Stock Options Granted FairValueOfStockOptionsGranted	75000	usd
CY2023Q2	avrw	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	115000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-987000	usd
	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-595000	usd
	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	1979000	usd
CY2024Q2	us-gaap	Cash Cash	19000	usd
CY2024Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	126000000.0	usd
CY2024Q2	avrw	Working Capital Deficit WorkingCapitalDeficit	12700000	usd
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	408000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	416000	usd
	avrw	Deferred Revenue Beginning Balance DeferredRevenueBeginningBalance	416000	usd
	avrw	Additions To Contract Liabilities AdditionsToContractLiabilities	37000	usd
	avrw	Contract Liabilities Customer Deposits Returned ContractLiabilitiesCustomerDepositsReturned	0	usd
	avrw	Contract Liabilities Transfers To Revenue ContractLiabilitiesTransfersToRevenue	-45000	usd
	avrw	Deferred Revenue Ending Balance DeferredRevenueEndingBalance	408000	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	185000	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	700000	usd
	us-gaap	Advertising Expense AdvertisingExpense	429000	usd
	us-gaap	Advertising Expense AdvertisingExpense	1500000	usd
CY2024Q2	avrw	Valuation Allowance Percentage ValuationAllowancePercentage	1	pure
CY2024Q2	avrw	Fair Value Of Series A Note FairValueOfSeriesANote	4907000	usd
CY2024Q2	avrw	Fair Value Of Series B Note FairValueOfSeriesBNote	3787000	usd
CY2023Q4	avrw	Fair Value Of Series A Note FairValueOfSeriesANote	4597000	usd
CY2023Q4	avrw	Fair Value Of Series B Note FairValueOfSeriesBNote	3502000	usd
	avrw	Notespayablefairvaluedisclosurebeginning Balance NotespayablefairvaluedisclosurebeginningBalance	8099000	usd
	avrw	Changes In Fair Value Of Series A Note ChangesInFairValueOfSeriesANote	310000	usd
	avrw	Change In Fair Value Of Series B Notes ChangeInFairValueOfSeriesBNotes	285000	usd
	avrw	Notes Payable Fair Value Disclosure Ending Balance NotesPayableFairValueDisclosureEndingBalance	8694000	usd
	avrw	Stock Price StockPrice	0.0519
CY2023	avrw	Stock Price StockPrice	0.0744
	avrw	Conversion Price ConversionPrice	1.32
CY2023	avrw	Conversion Price ConversionPrice	1.32
	avrw	Interest Rate InterestRate	0.180	pure
CY2023	avrw	Interest Rate InterestRate	0.180	pure
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-897000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-987000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2192000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1196000	usd
CY2024Q2	avrw	Weighted Average Common Shares Outstanding Basic And Diluted Shares WeightedAverageCommonSharesOutstandingBasicAndDilutedShares	77993348	shares
CY2023Q2	avrw	Weighted Average Common Shares Outstanding Basic And Diluted Shares WeightedAverageCommonSharesOutstandingBasicAndDilutedShares	71479697	shares
	avrw	Weighted Average Common Shares Outstanding Basic And Diluted Shares WeightedAverageCommonSharesOutstandingBasicAndDilutedShares	77993348	shares
	avrw	Weighted Average Common Shares Outstanding Basic And Diluted Shares WeightedAverageCommonSharesOutstandingBasicAndDilutedShares	71455716	shares
CY2024Q2	avrw	Basic And Diluted Loss Per Shares BasicAndDilutedLossPerShares	-0.01
CY2023Q2	avrw	Basic And Diluted Loss Per Shares BasicAndDilutedLossPerShares	-0.01
	avrw	Basic And Diluted Loss Per Shares BasicAndDilutedLossPerShares	-0.03
	avrw	Basic And Diluted Loss Per Shares BasicAndDilutedLossPerShares	-0.02
	avrw	Vested Stock Options From The Companys Equity Incentive Plan VestedStockOptionsFromTheCompanysEquityIncentivePlan	1435954	shares
	avrw	Vested Stock Options From The Companys Equity Incentive Plan VestedStockOptionsFromTheCompanysEquityIncentivePlan	1297491	shares
	avrw	Warrants Shares WarrantsShares	312500	shares
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	609925	shares
	avrw	Anti Dilutive Shares AntiDilutiveShares	1435954	shares
	avrw	Anti Dilutive Shares AntiDilutiveShares	2219916	shares
CY2024Q2	avrw	Customer Billed Accounts Receivable CustomerBilledAccountsReceivable	49000	usd
CY2023Q4	avrw	Customer Billed Accounts Receivable CustomerBilledAccountsReceivable	443000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	49000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	443000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	79000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	184000	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	15000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	7000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	69000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	101000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	286000	usd
CY2024Q2	avrw	Inventory Packaging Components InventoryPackagingComponents	60000	usd
CY2023Q4	avrw	Inventory Packaging Components InventoryPackagingComponents	84000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	372000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	408000	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	432000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	492000	usd
CY2024Q2	us-gaap	Inventory Adjustments InventoryAdjustments	-281000	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	-293000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	151000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	199000	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	0	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	37000	usd
CY2024Q2	us-gaap	Sale Leaseback Transaction Accumulated Depreciation SaleLeasebackTransactionAccumulatedDepreciation	7000	usd
CY2023Q4	us-gaap	Sale Leaseback Transaction Accumulated Depreciation SaleLeasebackTransactionAccumulatedDepreciation	5000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	1000	usd
	us-gaap	Depreciation Depreciation	2000	usd
	us-gaap	Depreciation Depreciation	1000	usd
CY2024Q2	avrw	Less Current Portion Of Notes Receivable LessCurrentPortionOfNotesReceivable	0	usd
CY2023Q4	avrw	Less Current Portion Of Notes Receivable LessCurrentPortionOfNotesReceivable	-975000	usd
CY2024Q2	avrw	Notes Receivable Non Current NotesReceivableNonCurrent	0	usd
CY2023Q4	avrw	Notes Receivable Non Current NotesReceivableNonCurrent	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	457000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	197000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	160000	usd
CY2024Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	261000	usd
CY2023Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	297000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	33000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	34000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	19000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	17000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	17000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	17000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	124000	usd
CY2024Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	261000	usd
CY2024Q2	avrw	Investment In Biopharmaceutical Research Company InvestmentInBiopharmaceuticalResearchCompany	213000	usd
CY2023Q4	avrw	Investment In Biopharmaceutical Research Company InvestmentInBiopharmaceuticalResearchCompany	213000	usd
CY2024Q2	us-gaap	Investments Investments	264000	usd
CY2023Q4	us-gaap	Investments Investments	264000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	568000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	568000	usd
CY2024Q2	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	581000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	566000	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	usd
CY2024Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	241000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	205000	usd
CY2024Q2	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	100000	usd
CY2023Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	81000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	209000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	154000	usd
CY2024Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	320000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	336000	usd
CY2024Q2	avrw	Accrued Expenses Current Net AccruedExpensesCurrentNet	1453000	usd
CY2023Q4	avrw	Accrued Expenses Current Net AccruedExpensesCurrentNet	1342000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	38000	usd
CY2024Q2	avrw	Accrued Interestrelatedpartiescurrent AccruedInterestrelatedpartiescurrent	2000	usd
CY2023Q4	avrw	Accrued Interestrelatedpartiescurrent AccruedInterestrelatedpartiescurrent	0	usd
CY2024Q2	avrw	Interest Expenses For Related Parties InterestExpensesForRelatedParties	1000	usd
CY2023Q2	avrw	Interest Expenses For Related Parties InterestExpensesForRelatedParties	0	usd
	avrw	Interest Expenses For Related Parties InterestExpensesForRelatedParties	2000	usd
	avrw	Interest Expenses For Related Parties InterestExpensesForRelatedParties	0	usd
CY2024Q2	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	31000	usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	139000	usd
CY2024Q2	avrw	Loan Payable Less Current Portion LoanPayableLessCurrentPortion	0	usd
CY2023Q4	avrw	Loan Payable Less Current Portion LoanPayableLessCurrentPortion	0	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	2000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	3000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	4000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	4000	usd
CY2024Q2	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	4907000	usd
CY2023Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	4597000	usd
CY2024Q2	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	3787000	usd
CY2023Q4	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	3502000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8694000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8099000	usd
CY2024Q2	avrw	Less Current Portion Of Convertible Promissory Notes At Fair Value LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue	-8694000	usd
CY2023Q4	avrw	Less Current Portion Of Convertible Promissory Notes At Fair Value LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue	-8099000	usd
CY2024Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.18	pure
CY2024Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
	us-gaap	Debt Conversion Description DebtConversionDescription	The Investor will not have the right to convert any portion of the Convertible Notes, to the extent that, after giving effect to such conversion, the Investor (and other certain related parties) would beneficially own in excess of 4.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion. This limit may, from time to time, be increased, up to 9.99%, or decreased
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	9500000	usd
	avrw	Warrant Exercisable Shares WarrantExercisableShares	4096272	shares
	avrw	Remaining Balance Of Investor Note RemainingBalanceOfInvestorNote	9400000	usd
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1518194	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	171000	usd
	avrw	Unrecognized Compensation Expense UnrecognizedCompensationExpense	42000	usd
	avrw	Weighted Average Remaining Contractual Life Year WeightedAverageRemainingContractualLifeYear	P1Y1M9D
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Cash Cash	1000000.0	usd
CY2023Q4	avrw	Shares Of Common Stock Earned SharesOfCommonStockEarned	4790419	shares
CY2023Q4	avrw	Remaining Shares Forfeited And Cancelled RemainingSharesForfeitedAndCancelled	1197605	shares
	avrw	Description Of Lease Agreement DescriptionOfLeaseAgreement	The lease agreement (the “Lease”), which expires on April 30, 2026, provides for the payment of base monthly rent in the amount of $7 thousand during the first 12 months of the term with an increase of 3% over the base monthly rent beginning on the one-year anniversary of the Lease. The Company previously occupied Suite 801 in the same building under a lease agreement that expired on April 30, 2024
	avrw	Weighted Average Discount Rate In Percentage WeightedAverageDiscountRateInPercentage	0.1416	pure
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	44000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Rolling Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextRollingTwelveMonths	91000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	23000	usd
CY2024Q2	avrw	Lessor Operating Lease Payments Undiscounted Cash Flow LessorOperatingLeasePaymentsUndiscountedCashFlow	158000	usd
CY2024Q2	us-gaap	Other Commitment OtherCommitment	19000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	139000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	146000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50000	usd
CY2024Q2	avrw	Right Of Use Lease Liabilities Current RightOfUseLeaseLiabilitiesCurrent	74000	usd
CY2023Q4	avrw	Right Of Use Lease Liabilities Current RightOfUseLeaseLiabilitiesCurrent	45000	usd
CY2024Q2	avrw	Right Of Use Lease Liability Noncurrent RightOfUseLeaseLiabilityNoncurrent	65000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	139000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	45000	usd
	avrw	Weighted Average Remaining Lease Term Operating Lease WeightedAverageRemainingLeaseTermOperatingLease	P1Y9M29D
CY2023	avrw	Weighted Average Remaining Lease Term Operating Lease WeightedAverageRemainingLeaseTermOperatingLease	P0Y3M14D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1416	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1130	pure
CY2024Q2	avrw	Additional Notes Tranches Amount AdditionalNotesTranchesAmount	350000	usd
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2024Q2	avrw	Lowest Trading Price Percentage Rate LowestTradingPricePercentageRate	0.70	pure
CY2024Q2	avrw	One Time Note Interest Charge Percentage Rate OneTimeNoteInterestChargePercentageRate	0.22	pure

Files In Submission

Name	View Source	Status
0001477932-24-004816-index-headers.html	Edgar Link	pending
0001477932-24-004816-index.html	Edgar Link	pending
0001477932-24-004816.txt	Edgar Link	pending
0001477932-24-004816-xbrl.zip	Edgar Link	pending
avrw-20240630.xsd	Edgar Link	pending
avrw_10q.htm	Edgar Link	pending
avrw_ex311.htm	Edgar Link	pending
avrw_ex312.htm	Edgar Link	pending
avrw_ex321.htm	Edgar Link	pending
avrw_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
avrw-20240630_def.xml	Edgar Link	unprocessable
avrw-20240630_lab.xml	Edgar Link	unprocessable
avrw-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
avrw_10q_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
avrw-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw

2024 Q3 Form 10-Q Financial Statement

#000147793224004816 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVRW Avenir Wellness Solutions, Inc. Stock $avrw

2024 Q3 Form 10-Q Financial Statement

#000147793224004816 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw